5 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Omacetaxine: new trials by email Literature Review of Omacetaxine trials Research Report on Omacetaxine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) Omacetaxine, Venetoclax - Relapsed or Refractory Hematologic Malignancies | Phase 1 | Completed | University of Illinois at Chicago | 6 | 2022-06-21 | 2026-03-16 |
| Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS Omacetaxine, Azacitidine - High Grade Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 29 | 2018-09-17 | 2026-11-06 |
| A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) Omacetaxine, Azacitidine, G-CSF - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Withdrawn | University of Florida | 2016-08-01 | 2017-05-03 | |
| Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure Omacetaxine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2015-05-18 | 2021-06-09 |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Omacetaxine, Decitabine - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 2 | 2015-05-06 | 2018-02-13 |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate omacetaxine mepesuccinate - Hematologic Malignancies, Solid Tumors | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 6 | 2013-07-01 | 2015-01-30 |
| Omacetaxine for Consolidation and Maintenance Omacetaxine - Acute Myelogenous Leukemia (AML) | Phase 2 | Terminated | Emory University | 7 | 2013-05-01 | 2019-09-24 |
| Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Omacetaxine, Cytarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 36 | 2011-07-01 | 2018-05-30 |
| Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors Omacetaxine - Hematologic Tumors | Phase 1 | Completed | ChemGenex Pharmaceuticals | 12 | 2008-04-01 | 2014-05-12 |
Leukemia (3) · Leukemia, Myeloid, Acute (3) · Hematologic Neoplasms (2) · Myelodysplastic Syndromes (2) · Recurrence (1)
M.D. Anderson Cancer Center (3) · ChemGenex Pharmaceuticals (1) · Emory University (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · University of Colorado, Denver (1) · University of Florida (1) · University of Illinois at Chicago (1)
United States (8) · Netherlands (1)
Elias Jabbour, MD (2) · Daniel Pollyea, MD (1) · Hagop Kantarjian, MD (1) · John Nemunaitis, M.D. (1) · John Quigley, MD (1) · Martha L. Arellano, MD (1) · Maxim N. Norkin, MD, PhD (1)